Novo Nordisk said Wednesday it would offer lower-priced doses of its weight loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States.

Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.

The doses, offered through a program called NovoCare Pharmacy, will be available for uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines, the company said.

The move comes after the U.S. Food and Drug Administration said on February 21 that there was no longer a shortage of Novo Nordisk's weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.